On-Prem AI Gains Traction for Biotech

KALA BIO has entered into a Platform Development and Exclusive License Agreement with a company called Younet AI for a proprietary AI research platform known as "Researgency". This agreement gives KALA an exclusive worldwide license to the Researgency platform within the biotechnology field for an initial 12-month term, with options to renew. The deal includes up to $530,000 in initial cash payments and the issuance of 5 million KALA common shares to Younet. The Researgency platform is designed to deploy custom, secure large language models specifically for biomedical research and data science. It includes features like retrieval-augmented generation pipelines and AI agents tailored for functions such as analyzing protein interactions, reviewing drug safety literature, and modeling clinical trial outcomes. This architecture is intended to differentiate KALA from centralized AI platforms by allowing biotech firms to use institutional-grade AI without their data ever leaving their own servers. KALA will first act as its own client to validate the platform. The company will apply Researgency's AI to its proprietary mesenchymal stem cell secretome (MSC-S) platform datasets and its KPI-012 clinical program for persistent corneal epithelial defect. Preliminary findings from this internal use are expected to be reported within the initial 12-month term. This strategic shift comes as the clinical-stage biopharmaceutical company's stock has fallen nearly 95% over the past year. The move positions KALA to generate recurring revenue through a platform-as-a-service (PaaS) model, licensing its AI capabilities to other biotech and pharmaceutical companies after the internal validation phase. The broader biotech industry's use of AI is surging, with workloads like genomic analysis, protein folding, and clinical trial modeling demanding massive, secure compute infrastructure. The on-premise model directly addresses major industry vulnerabilities, such as protecting intellectual property, ensuring patient data privacy under regulations like HIPAA, and preventing cyberattacks on sensitive research data. This on-premise approach contrasts with cloud-based AI, offering organizations tighter control over data security and potentially lower long-term operational costs for sustained workloads, despite higher upfront hardware investments. For biotech, where datasets are massive and proprietary, the "data-sovereign" model prevents intellectual property from being exposed to public or third-party cloud services.